Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Declines By 73.6%

Posted by Brian Himes on Jul 13th, 2026

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 74,316 shares, a decline of 73.6% from the June 15th total of 281,382 shares. Currently, 1.7% of the company’s shares are short sold. Based on an average daily volume of 129,618 shares, the short-interest ratio is presently 0.6 days.

Galmed Pharmaceuticals Stock Down 1.8%

NASDAQ:GLMD traded down $0.01 on Friday, hitting $0.56. The stock had a trading volume of 25,422 shares, compared to its average volume of 122,764. Galmed Pharmaceuticals has a 52 week low of $0.41 and a 52 week high of $2.34. The business’s fifty day moving average is $0.60 and its 200 day moving average is $0.65. The company has a market cap of $3.07 million, a PE ratio of -0.45 and a beta of 0.75.

Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings results on Wednesday, July 8th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 76.14% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Galmed Pharmaceuticals presently has a consensus rating of “Sell”.

Get Our Latest Report on Galmed Pharmaceuticals

Galmed Pharmaceuticals Company Profile

(Get Free Report)

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.